Definitive Contract HHSN261201000132C

The U.S. National Cancer Institute (NCI) awarded a $1,499,990.00 cost-plus-award-fee contract to Insight Genetics, Inc. for research and development in the biomedical basic research field. The contract, which has a performance period through September 19, 2015, was awarded on September 20, 2013 and does not have a set-aside designation. While the original solicitation is not provided, this contract appears to be part of the NCI's larger research and development efforts in the medical and...

This is a $1,698,988.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services (HHS), to Insight Genetics, Inc., a small business. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a total small business set-aside designation. The contract was awarded on September 20, 2012 and has an ultimate completion date of August 16, 2015. This contract award is not associated...

<p>This is a $1,494,102.45 cost-plus-fixed-fee contract awarded by the National Cancer Institute (a civilian agency) to Insight Genetics, Inc., a small business. The contract is for the development of a companion diagnostic for ALK mutations. It was awarded on September 28, 2012 and has a final completion date of February 5, 2015. This appears to be a stand-alone contract and not part of a larger contract vehicle.</p>

This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency, to Insight Genetics, Inc., a small business. The $193,637 firm-fixed-price contract is for the development of a clinical diagnostic assay to detect ALK inhibitor resistance mutations under the SBIR (Small Business Innovation Research) program. The contract has a period of performance through July 31, 2012 and was awarded on September 30, 2011. As an SBIR award, this contract was set aside for...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Incogen Inc., a woman-owned small business. The contract, valued at $3,599,936, is for the development of &quot;GENE EXPRESSION SIGNAL PROCESSING TOOLS FOR EARLY DETECTION OF CANCER&quot; under Topic 197. It is a definitive, firm-fixed-price contract with a period of performance ending on December 14, 2009. The contract is set aside for small businesses.

This definitive firm fixed price contract was awarded by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, to Digital Nanogenetics LLC on September 17, 2018. With a potential value of $300,000, the contract is associated with the Small Business Innovation Research Program Phase I and has a completion date of September 19, 2019. The contract has a set aside designation for total small businesses and will support research...

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

The National Cancer Institute awarded a $224,997.00 firm fixed-price definitive contract to Paganini Biopharma, Inc. for research and development in biomedical basic research. The contract has a performance period ending on September 17, 2015 and was awarded on September 18, 2014. This contract was not set aside for any specific business type. The National Cancer Institute is a civilian agency within the U.S. Department of Health and Human Services that conducts and supports cancer research.

<p>This is a $198,751 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Genomic Systems, LLC. The contract is for research and development in the TAS::75 0849::TAS area and has a period of performance ending on September 30, 2011. This SBIR Phase I contract was awarded on a Firm Fixed Price basis.</p>